Edgewise Therapeutics (EWTX) Other Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Other Accumulated Expenses data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 14.34% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 14.34% YoY), and the FY2025 full-year result was $759000.0, up 2.43% from the prior year.
• Other Accumulated Expenses rose to $1.2 million in Q1 2026, from $759000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q1 2026 to a low of $399000.0 in Q4 2023.
• A 5-year average of $830529.4 and a median of $804000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 235.77% in 2022 and slumped 62.29% in 2023, its largest moves.
• Tracing EWTX's Other Accumulated Expenses over 5 years: stood at $1.1 million in 2022, then plunged by 62.29% to $399000.0 in 2023, then jumped by 85.71% to $741000.0 in 2024, then gained by 2.43% to $759000.0 in 2025, then surged by 56.52% to $1.2 million in 2026.
• Business Quant data shows EWTX's Other Accumulated Expenses at $1.2 million in Q1 2026, $759000.0 in Q4 2025, and $714000.0 in Q3 2025.